Abbott Capitulates In Continuous Glucose Deal: Can SpectRx Go It Alone?
This article was originally published in The Gray Sheet
Executive Summary
SpectRx likely will have to find another development partner for FDA pivotal studies of its consumer continuous glucose monitoring device after initiating termination of a joint R&D and license agreement with Abbott Laboratories Jan. 7
You may also be interested in...
SpectRx’ Double Play: Extend SimpleChoice Line, Ink Glucose Monitor Partner
SpectRx could be cash-flow neutral in 2005 if SimpleChoice diabetes management product line sales increase as expected, CFO Thomas Muller predicted during a March 31 earnings call
SpectRx’ Double Play: Extend SimpleChoice Line, Ink Glucose Monitor Partner
SpectRx could be cash-flow neutral in 2005 if SimpleChoice diabetes management product line sales increase as expected, CFO Thomas Muller predicted during a March 31 earnings call
Abbott Acquires A Future For Its Diabetes Care Business; Where’s Bayer?
Access to a development partnership with insulin infusion pump manufacturer Smiths Medical could prove a critical component of Abbott Labs' $1.2 bil. purchase of diabetes management firm TheraSense